deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 3-arm NCT02912949

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)

Sponsor: Partner Therapeutics, Inc.

Updated 25 times since 2017 Last updated: Apr 25, 2025 Started: Jan 31, 2015 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates NRG1 Fusion and NSCLC Harboring NRG1 Fusion and is currently ongoing. Partner Therapeutics, Inc. leads this study, which shows 25 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2018 · 14 months · monthly snapshot~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshot~Apr 2019 – ~Sep 2019 · 5 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Jun 2020 · 4 months · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2022 · 19 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Feb 2024 · 13 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Jan 2025 · 2 months · monthly snapshot~Jan 2025 – ~Mar 2025 · 59 days · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

25 versions recorded
  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. May 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Apr 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2025 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  5. Jan 2025 — Mar 2025 [monthly]

    Recruiting PHASE2

Show 20 earlier versions
  1. Nov 2024 — Jan 2025 [monthly]

    Recruiting PHASE2

  2. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Feb 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  5. Jan 2023 — Feb 2024 [monthly]

    Recruiting PHASE2

  6. Sep 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

    Phase: PHASE1_PHASE2PHASE2

  7. Feb 2021 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1_PHASE2

  9. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  10. Aug 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jun 2020 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

  12. Feb 2020 — Jun 2020 [monthly]

    Recruiting PHASE1_PHASE2

  13. Nov 2019 — Feb 2020 [monthly]

    Recruiting PHASE1_PHASE2

  14. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  15. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Unknown StatusRecruiting

  16. Apr 2019 — Sep 2019 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: RecruitingUnknown Status

  17. Jun 2018 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  18. Apr 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  19. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE1_PHASE2

  20. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Partner Therapeutics, Inc.
Data source: Partner Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .